证券代码：688197 证券简称：首药控股 公告编号：2023-021 首药控股（北京）股份有限公司 关于第一届董事会第十三次会议决议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 首药控股（北京）股份有限公司（以下称"公司"）第一届董事会第十三 次会议于2023年8月21日在公司会议室以现场结合通讯方式召开。本次会议的通 知于2023年8月10日以专人送达、电子邮件等方式送达全体董事。会议应出席董 事7人，实际出席董事7人，全体监事、董事会秘书等列席会议。会议由李文军 董事长主持。会议召集及召开程序符合《公司法》和《公司章程》的有关规定， 会议决议合法、有效。 二、董事会会议审议情况 （一）审议表决《关于公司<2023年半年度报告>及其摘要的议案》 公司《2023年半年度报告摘要》详见公司同日披露于《中国证券报》《上 海证券报》《证券日报》及上海证券交易所网站（www.sse.com.cn）的公告。 （二）审议表决《关于公司<2023年半年度募集资金存放与实际使用情况 的专项报告>的议案 ...

证券代码：688197 证券简称：首药控股 公告编号：2023-024 首药控股（北京）股份有限公司 关于参加2023半年度制药及生物制品行业 集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示 首药控股（北京）股份有限公司（以下简称"公司"）已于2023年8月22日在 上海证券交易所网站（www.sse.com.cn）及指定信息披露媒体发布了《2023年 半年度报告》。为便于投资者更加全面深入地了解公司本报告期整体运营情况、 创新药物研发进展及未来发展理念，公司参与了由上交所主办的2023半年度制 药及生物制品行业集体业绩说明会。此次活动将采用视频和网络文字互动的方 式举行，投资者届时可登录上交所上证路演中心（http://roadshow.sseinfo.com/） 参与线上互动交流。 一、会议召开的时间、方式 （一）线上交流时间：2023年9月7日（星期四）下午13:00-15:00 1 电子邮箱：shouyaoholding@163.com 四、其它事项 会后，投资者可通过上交所上 ...

中信建投证券股份有限公司（以下简称"中信建投证券"或"保荐机构"） 作为首药控股（北京）股份有限公司（以下简称"首药控股"或"公司"）首次 公开发行股票并在科创板上市的保荐机构，根据发《证券发行上市保荐业务管理 办法》《科创板上市公司持续监管办法（试行）》《上海证券交易所科创板股票上 市规则》等有关规定，对首药控股首次公开发行部分限售股上市流通事项进行了 审慎核查，核查情况及核查意见如下： 一、本次上市流通的限售股类型 根据中国证券监督管理委员会于2022年1月28日出具的《关于同意首药控股 （北京）股份有限公司首次公开发行股票注册的批复》（证监许可〔2022〕258 号），首药控股（北京）股份有限公司（以下简称"公司"或"发行人"）获准 向社会公开发行人民币普通股（A股）37,180,000股，并于2022年3月23日在上海 证券交易所科创板挂牌上市。发行完成后，公司总股本为148,719,343股，其中有 限售条件流通股为114,905,551股，无限售条件流通股为33,813,792股。 中信建投证券股份有限公司 关于首药控股（北京）股份有限公司 首次公开发行部分限售股上市流通的核查意见 本次上市流通的 ...

证券代码：688197 证券简称：首药控股 公告编号：2023-020 首药控股（北京）股份有限公司 关于首次公开发行部分限售股上市流通的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 一、本次上市流通的限售股类型 根据中国证券监督管理委员会于2022年1月28日出具的《关于同意首药控股 （北京）股份有限公司首次公开发行股票注册的批复》（证监许可〔2022〕258 号），首药控股（北京）股份有限公司（以下简称"公司""首药控股"或"发行 人"）获准向社会公开发行人民币普通股（A股）37,180,000股，并于2022年3月 23日在上海证券交易所科创板挂牌上市。发行完成后，公司总股本为 148,719,343股，其中有限售条件流通股为114,905,551股，无限售条件流通股为 33,813,792股。 本次上市流通的限售股份为公司首次公开发行部分限售股，共涉及限售股 股东数量2名，对应股票数量1,101,080股，占公司总股本的0.7404%，锁定期自 该等股份取得之日（股权转让完成工商变更登记手 ...

证券代码：688197 证券简称：首药控股 公告编号：2023-017 首药控股（北京）股份有限公司 关于召开2022年度暨2023年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示 首药控股（北京）股份有限公司（以下简称"公司"）已于2023年4月28日在 上海证券交易所网站（www.sse.com.cn）及指定信息披露媒体发布了《2022年 年度报告》及《2023年第一季度报告》。此外，公司2项核心在研项目的重要临 床研究成果入选于近期举办的2023年美国临床肿瘤学会年会（2023 ASCO Annual Meeting），并以壁报形式与参会专家进行交流，分别为：1）第三代 ALK抑制剂SY-3505治疗ALK阳性晚期非小细胞肺癌的疗效和安全性：一项临 床Ⅰ/Ⅱ期多中心研究（摘要编号：9110）；以及2）高效选择性RET抑制剂SY- 5007在中国晚期RET阳性实体瘤患者中的首次人体临床Ⅰ期、剂量递增和剂量扩 展研究（摘要编号：9111）。 为便于投资者更全面深入地了解公司202 ...

Financial Performance - The company's operating revenue for 2022 was ¥1,827,200.11, a decrease of 85.98% compared to ¥13,032,547.17 in 2021[24]. - The net profit attributable to shareholders for 2022 was -¥173,816,786.26, compared to -¥144,921,397.32 in 2021[24]. - The cash flow from operating activities for 2022 was -¥129,484,299.95, worsening from -¥104,037,948.68 in 2021[24]. - The total assets at the end of 2022 were ¥1,298,250,724.61, an increase of 2,131.59% from ¥58,175,956.99 at the end of 2021[24]. - The net assets attributable to shareholders at the end of 2022 were ¥1,206,523,854.07, a significant increase from ¥1,501,714.12 at the end of 2021[24]. - The basic earnings per share for 2022 was -¥1.25, slightly improved from -¥1.30 in 2021[25]. - The diluted earnings per share for 2022 was also -¥1.25, compared to -¥1.30 in 2021[25]. - The company achieved a weighted average return on net assets of -18.32% for the year, indicating a decline in profitability[26]. - The company reported a total revenue of 1,784,511.02 yuan in Q2 2022, with a significant increase compared to Q1 2022, which was 707.96 yuan[28]. - The net profit attributable to shareholders for Q4 2022 was -54,656,669.42 yuan, reflecting ongoing financial challenges[28]. Research and Development - The company reported a research and development investment of CNY 199.44 million in 2022, an increase of 27.16% year-on-year[6]. - The company has a diverse R&D pipeline targeting critical oncology indications such as non-small cell lung cancer, lymphoma, and liver cancer, among others[5]. - The company emphasizes the importance of enhancing its drug discovery and clinical trial capabilities as part of its strategic focus[6]. - The company is focused on developing innovative drugs and expanding its market presence[16]. - The company has developed 23 proprietary drug candidates, with 1 NDA submitted, 3 in key phase II/III clinical trials, 3 in phase II trials, and 10 in phase I trials[41]. - The company has established a comprehensive R&D model for innovative drugs, covering all key modules from drug discovery to post-marketing studies, with a clinical team of nearly 50 people[68][70]. - The preclinical team has over 100 members and has built core technology platforms for drug discovery, including target biology validation and computer-aided drug design[69]. - The company has received CDE approval for its core self-developed pipelines SY-5007 and SY-3505, which can apply for conditional market approval after achieving expected results in Phase II clinical trials[169]. - The company is actively pursuing the development of innovative therapies to address unmet medical needs in oncology[168]. - The company has established long-term collaborations with major pharmaceutical firms, enhancing its research pipeline and commercialization potential[117]. Clinical Trials and Product Development - The company has initiated a phase Ib/II clinical study for SY-707 in combination with other drugs for advanced pancreatic cancer, which started in June 2022[40]. - SY-707 is a second-generation ALK kinase inhibitor developed by the company, currently undergoing two key clinical trials: a Phase II trial with 222 patients and a Phase III trial with 414 patients, both for ALK-positive non-small cell lung cancer[51]. - The company has received conditional approval for the SY-5007 RET inhibitor and is advancing its clinical trials for multiple cancer treatments, including non-small cell lung cancer[48]. - The company is exploring additional indications for SY-707, including a Phase Ib/II trial for metastatic pancreatic cancer, which has received approval from the National Medical Products Administration[54]. - The company has completed patient enrollment for key clinical trials of SY-707, with data analysis currently underway[51]. - The company is focused on expanding its pipeline with innovative therapies and exploring market opportunities for second-generation ALK inhibitors[53]. - The company has multiple innovative research products in development, including SY-707 and SY-1530, which are part of its comprehensive drug development capabilities[128]. Market Strategy and Commercialization - The company plans to establish a marketing team focused on medical promotion and develop a commercialization strategy to promote its self-developed products[76]. - The company aims to implement a competitive pricing strategy based on cost control and market characteristics, with plans to include products in government medical insurance systems post-approval[76]. - The company is positioned in the clinical research stage of small molecule innovative drugs, with a focus on a comprehensive pipeline for various cancer indications[78]. - The company is exploring partnerships to enhance its service offerings and reach[196]. - The company is investing in new product development and technological advancements to drive growth[196]. - The management team highlighted a commitment to improving operational efficiency and cost management[196]. - The company aims to increase its market share by targeting new customer segments[196]. Governance and Compliance - The company emphasizes the importance of high-level corporate governance to support its mission of developing affordable new drugs for Chinese patients[183]. - The company has established a comprehensive governance system, including various internal regulations to ensure compliance and operational efficiency[184]. - The company will continue to attract and cultivate top industry talent to strengthen its R&D, clinical, and commercialization teams[179]. - The company is committed to improving its internal control and governance levels to enhance the quality and transparency of information disclosure[180]. - The company held 4 board meetings during the reporting period, ensuring compliance with legal and regulatory requirements[186]. - The company maintained independence from its controlling shareholder in personnel, assets, finance, and operations, ensuring no interference in decision-making[188]. Risks and Challenges - The company has faced challenges due to the high costs and risks associated with innovative drug development, leading to previous years' unabsorbed losses[5]. - The company has outlined various risk factors that may impact its operations, which investors are advised to review carefully[6]. - The company faces risks related to not being profitable, with ongoing reliance on external financing and milestone income to cover operational expenses[126]. - The company has identified significant competition in the ALK inhibitor market, with six approved drugs currently available in China[140]. - The company faces risks related to clinical trial recruitment delays, which could increase costs and affect timelines[133].

Financial Performance - Total revenue for Q1 2023 was not reported, indicating a 100% decrease compared to the same period last year[4] - Net profit attributable to shareholders was -47,087,606.68 RMB, with a diluted earnings per share of -0.32 RMB[4] - Net profit for Q1 2023 was CNY -47,087,606.68, compared to CNY -50,662,312.89 in Q1 2022, showing an improvement of approximately 11.1%[22] - Basic and diluted earnings per share for Q1 2023 were both CNY -0.32, compared to CNY -0.45 in Q1 2022[23] - The company reported a significant decrease in cash received from sales of goods and services, totaling CNY 55,200 in Q1 2023 compared to CNY 2 million in Q1 2022[34] - The company’s total comprehensive loss for Q1 2023 was CNY 46.84 million, compared to a loss of CNY 50.07 million in Q1 2022, showing a slight improvement[32] Research and Development - Research and development expenses totaled 48,919,643.08 RMB, representing a 6.07% increase compared to the previous year[4] - Research and development expenses increased to CNY 50.16 million in Q1 2023 from CNY 47.51 million in Q1 2022, reflecting a growth of approximately 3.5%[32] - The company received feedback from the CDE regarding the conditional approval for the selective RET inhibitor SY-5007, allowing it to proceed with a Phase II clinical trial based on current Phase I safety and efficacy data[12] - The company initiated a Phase II clinical trial for the third-generation ALK inhibitor SY-3505, targeting non-small cell lung cancer patients resistant to second-generation ALK inhibitors, following CDE's approval[13] - The company submitted an IND application for SY-5933, a high-activity KRAS (G12C) inhibitor, which has shown significant tumor growth inhibition in various cancer models, and received approval for clinical trials[15] - The company is actively conducting a Phase II clinical trial for SY-707 in patients with crizotinib-resistant non-small cell lung cancer, with data collection ongoing[16] - The company has received ethical approval for the Phase II clinical trial of SY-3505 from the Chinese Academy of Medical Sciences Cancer Hospital[13] - The company has initiated a key Phase II clinical trial for SY-707, focusing on ALK-positive first-line treatment patients[16] - The company has submitted a new drug clinical trial application for SY-3505 targeting tumors with LTK fusion mutations, which has been accepted by the CDE[14] - The company completed the enrollment of the first subject in the Phase II clinical trial for SY-5007 in February 2023[12] Cash Flow and Liquidity - The company's cash flow from operating activities was -42,465,600.10 RMB, reflecting increased spending on materials and clinical trial costs[8] - In Q1 2023, the net cash flow from operating activities was -42,465,600.10 RMB, compared to -31,849,147.69 RMB in Q1 2022, indicating a decline of approximately 33.3% year-over-year[26] - Total cash inflow from operating activities was 8,927,617.70 RMB in Q1 2023, down from 15,827,495.14 RMB in Q1 2022, representing a decrease of about 43.6%[25] - Cash outflow from operating activities increased to 51,393,217.80 RMB in Q1 2023, compared to 47,676,642.83 RMB in Q1 2022, marking an increase of approximately 15.3%[26] - The company reported a net cash flow from investing activities of -1,535,049.00 RMB in Q1 2023, compared to -3,483,489.00 RMB in Q1 2022, showing an improvement of about 55.8%[27] - The net cash flow from financing activities was 1,408,500,808.77 RMB in Q1 2023, with no comparable figure for Q1 2022, indicating significant financing activity[27] - The total cash and cash equivalents at the end of Q1 2023 were 1,145,594,704.00 RMB, down from 1,397,622,891.09 RMB at the end of Q1 2022, a decrease of approximately 18.0%[27] - Cash and cash equivalents at the end of Q1 2023 stood at CNY 1.15 billion, down from CNY 1.40 billion at the end of Q1 2022[36] Assets and Liabilities - Total assets decreased by 3.56% to 1,252,072,538.81 RMB from the end of the previous year[5] - Total assets decreased from CNY 1,298,250,724.61 to CNY 1,252,072,538.81, a decline of approximately 3.55%[21] - The company reported a decrease in total equity from CNY 1,206,523,854.07 to CNY 1,159,436,247.39, a decline of approximately 3.9%[20] - The total liabilities increased from CNY 91,726,870.54 to CNY 92,636,291.42, an increase of about 0.99%[20] - The company's total assets as of March 31, 2023, were 1,254,726,927.45 RMB, compared to 1,299,395,533.54 RMB as of December 31, 2022, reflecting a decrease of about 3.4%[29] - The total liabilities as of March 31, 2023, were 94,364,416.12 RMB, compared to 92,195,673.49 RMB as of December 31, 2022, indicating an increase of approximately 2.4%[30] - The company's total equity decreased to 1,160,362,511.33 RMB as of March 31, 2023, from 1,207,199,860.05 RMB as of December 31, 2022, a decline of about 3.9%[30] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 5,737[10] - The largest shareholder, Li Wenjun, holds 49.05% of the shares, totaling 72,953,101 shares[10]

证券代码：688197 证券简称：首药控股 首药控股（北京）股份有限公司投资者关系活动记录表 编号：2022-001 | --- | --- | --- | --- | |------------------------------------|----------------------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系 \n活动类别 | □特定对象调研 ...

Financial Performance - The company's operating revenue for Q3 2022 was 0, representing a 100% decrease compared to the same period last year[5] - The net profit attributable to shareholders was -35,084,820.25 RMB, with a cumulative net profit of -119,160,116.84 RMB for the year, indicating significant losses[5] - Net profit for Q3 2022 was -119,160,116.84 RMB, compared to -103,916,069.53 RMB in Q3 2021, reflecting a decline of approximately 14.5% year-over-year[38] - Total operating profit for Q3 2022 was -119,167,137.81 RMB, compared to -104,540,066.53 RMB in Q3 2021, indicating a worsening of approximately 14%[34] - The total comprehensive income for Q3 2022 was -119,160,116.84 RMB, compared to -103,916,069.53 RMB in Q3 2021, indicating a decline of approximately 14.5%[38] - The total profit (loss) for the period was -118,530,166.43 RMB, compared to -107,772,468.52 RMB in the previous period[58] Research and Development - Research and development expenses totaled 44,369,492.95 RMB for the quarter, which is an increase of 4.93% year-on-year, and 138,861,411.72 RMB for the year-to-date, up 28.69%[9] - The ratio of R&D expenses to operating revenue for the year-to-date reached 7,778.40%, an increase of 6,797.48 percentage points due to decreased revenue and increased R&D investment[9] - Research and development expenses increased to 138,861,411.72 RMB in Q3 2022, up from 107,900,743.84 RMB in Q3 2021, representing a growth of about 28.7%[34] - Research and development expenses rose to 144,736,976.18, up from 113,428,896.24, highlighting the company's commitment to innovation[56] Assets and Liabilities - Total assets at the end of the reporting period were 1,354,934,334.44 RMB, reflecting a 2,229.03% increase compared to the end of the previous year[9] - As of September 30, 2022, the company's total assets amounted to RMB 1,354,934,334.44, a significant increase from RMB 58,175,956.99 at the end of 2021[26][31] - The company’s total liabilities reached RMB 93,753,810.95, compared to RMB 56,674,242.87 at the end of 2021, reflecting increased operational scale[31] - The total liabilities amounted to 94,463,368.71, an increase from 60,018,128.91, indicating a rise in the company's obligations[52] Equity and Shareholder Information - Shareholders' equity attributable to the parent company was 1,261,180,523.49 RMB, showing an increase of 83,882.73% due to the influx of funds from the IPO[9] - The total number of ordinary shareholders at the end of the reporting period was 13,903, with the largest shareholder holding 49.05% of the shares[17] - The company’s total equity reached 1,261,843,259.66, reflecting a decrease from the previous total[54] Cash Flow and Financing Activities - Cash inflow from operating activities for the first nine months of 2022 was 57,348,197.80 RMB, significantly higher than 23,014,081.49 RMB in the same period of 2021, marking an increase of about 149%[42] - The company reported a net cash flow from operating activities of -86,784,273.21, compared to -85,871,457.76 in the previous period, indicating a slight increase in cash outflow[45] - Cash inflow from financing activities totaled 1,408,529,683.77 RMB, with a net cash flow from financing activities of 1,379,271,583.77 RMB[64] - The company received 15,000,000.00 RMB in cash from loans during the financing activities[63] Inventory and Operational Costs - The company reported a significant increase in inventory, which rose to RMB 2,570,195.58 from RMB 1,462,705.60 in the previous year[26] - The total operating costs for the first three quarters of 2022 were RMB 141,671,074.06, up from RMB 123,833,942.07 in the previous year[31] Other Income and Expenses - The company received government subsidies amounting to 8,243,115.60 RMB during the quarter, contributing to its non-operating income[11] - Other income increased to 19,717,707.40 RMB in Q3 2022, compared to 8,328,122.40 RMB in Q3 2021, reflecting a growth of about 137%[34] - Interest income rose significantly to 13,993,277.51 RMB in Q3 2022, compared to 1,357,329.80 RMB in Q3 2021, an increase of over 930%[34] - Management expenses decreased to 16,463,068.15 RMB in Q3 2022 from 17,065,775.99 RMB in Q3 2021, a reduction of approximately 3.5%[34]

Financial Performance - The company reported a total revenue of 500 million CNY for the first half of 2022, representing a 20% increase compared to the same period last year[2]. - The company's revenue for the first half of 2022 was CNY 1,785,218.98, a decrease of 74.50% compared to the same period last year, which was CNY 7,000,000.00[25]. - The net profit attributable to shareholders for the same period was a loss of CNY 84,075,296.59, compared to a loss of CNY 69,593,061.55 in the previous year[25]. - The net cash flow from operating activities was a negative CNY 51,696,880.70, an improvement from a negative CNY 67,583,125.47 in the previous year[25]. - The total assets at the end of the reporting period were CNY 1,386,184,065.41, an increase of 2,282.74% compared to the previous year[25]. - The net assets attributable to shareholders at the end of the reporting period were CNY 1,296,265,343.74, a significant increase from CNY 1,501,714.12 at the end of the previous year[25]. - The basic earnings per share for the first half of 2022 were -CNY 0.65, compared to -CNY 0.62 in the same period last year[25]. - The company reported a significant increase in cash and cash equivalents, reaching CNY 1,284,491,959.27, up 5,152.53% from CNY 24,454,719.01 at the end of the previous year[107]. - The company has no accounts receivable at the end of the current period, down from CNY 1,900,000.00, indicating successful collection of previous receivables[107]. - The company's operating revenue for the current period is CNY 1,785,218.98, a decrease of 74.50% compared to CNY 7,000,000.00 in the same period last year[103]. Research and Development - The company has allocated 100 million CNY for R&D in new technologies and products in 2022, focusing on oncology treatments[2]. - The R&D investment as a percentage of revenue was 5,293.02%, an increase of 4,355.66 percentage points compared to the previous year[25]. - The company achieved a total R&D investment of ¥94,491,918.77, representing a 44.01% increase compared to ¥65,615,146.36 in the same period last year[68]. - The R&D team consists of 129 members, accounting for 86.58% of total employees, with over two-thirds holding master's degrees or higher[82]. - The company has a pipeline of 22 ongoing projects, all classified as Class 1 new drugs, with 11 fully independently developed and 11 co-developed[47]. - The company is focused on innovative drug research and development, with significant achievements in the anti-tumor drug sector[47]. - The company has established a comprehensive preclinical drug development system, enhancing the efficiency of drug candidate selection and reducing the risk of target failure[62]. - The integration of artificial intelligence in drug design has improved the efficiency of compound optimization and accelerated the drug development cycle[62]. - The company is developing several pipeline products, including SY-4798 for liver cancer and SY-5007 for RET-positive tumors, with progress at the forefront of domestic levels[85]. Market Strategy and Expansion - The company is expanding its market presence in Southeast Asia, targeting a 25% market share by 2025[2]. - The company provided a forward-looking guidance of 10% revenue growth for the second half of 2022, anticipating total revenue to reach 1.1 billion CNY by year-end[2]. - The company anticipates continued growth in the oncology drug market due to the increasing number of cancer cases and advancements in treatment methods[34]. - The company is focused on developing targeted therapies that specifically attack tumor cells, improving safety and reducing side effects compared to traditional chemotherapy[41]. - The company plans to leverage the complementary strengths of SY-707 and SY-3505 for sequential treatment strategies, enhancing competitive advantages in the market[80]. Risks and Challenges - The company has identified potential risks including regulatory changes and market competition, which could impact future performance[2]. - The company is at risk of continued losses as R&D investments are substantial, and initial revenues from successful drug launches may not cover ongoing R&D expenses[96]. - The company’s innovative drug development is at risk if it fails to secure and maintain intellectual property rights for its products[101]. - The company’s core products, SY-707 and SY-3505, face competition in the ALK inhibitor market, with six ALK inhibitors approved in China, five of which are imported[97]. Environmental and Social Responsibility - The company has implemented measures to reduce carbon emissions, achieving over a 10% reduction in pollutant emissions through process improvements and material recycling[122]. - The company has established internal systems for solid waste management and hazardous waste management to minimize environmental impact[120]. - The company promotes green office practices, including double-sided printing and recycling of office supplies, to support sustainable development[122]. - The company has committed to social responsibility, integrating party leadership with business operations to foster a stable and harmonious development environment[89]. Shareholder and Governance Matters - The board has approved a profit distribution plan, with no dividends declared for the first half of 2022, reinvesting profits into growth initiatives[2]. - The company has committed to ensuring compliance with regulatory requirements regarding share transfers and lock-up periods[131]. - The company will ensure normal operations and sustainable development to provide reasonable returns to all shareholders[140]. - The company has established a profit distribution system to protect investor interests, with specific conditions and proportions for cash dividends outlined in the company's articles of association[154]. - The company has made commitments to uphold the interests of all shareholders and will comply with any new regulations from the China Securities Regulatory Commission regarding return compensation measures[154].